Oct 11, 2024 9:15 am EDT Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress
Oct 09, 2024 9:15 am EDT Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
Oct 04, 2024 9:15 am EDT Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society Congress
Sep 24, 2024 8:00 am EDT Capricor Therapeutics Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy
Sep 23, 2024 9:25 am EDT Capricor Therapeutics to Provide Duchenne Muscular Dystrophy Program Update on September 24, 2024
Sep 17, 2024 9:15 am EDT Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular Dystrophy
Sep 06, 2024 8:30 am EDT Capricor Therapeutics to Present at Upcoming Investor and Scientific Conferences
Aug 07, 2024 4:05 pm EDT Capricor Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Jul 31, 2024 9:00 am EDT Capricor Therapeutics to Present Second Quarter 2024 Financial Results and Recent Corporate Update on August 7